This impressive growth was driven by strong sales of its drugs, FIRDAPSE and AGAMREE. Additionally, Catalyst has maintained a strong financial position with over $500 million in cash. The company ...
The announcement follows finalised recommendations this week that backed Agamree (vamorolone) as a treatment for patients aged four and over with DMD from the National Institute for Health and ...
This impressive growth was driven by strong sales of its drugs, FIRDAPSE and AGAMREE. Additionally, Catalyst has maintained a strong financial position with over $500 million in cash. The company's ...
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...
At close: 24 January at 3:00:00 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback